Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant GC Chemotherapy vs Surgery in High-Grade UTUC
NCT02876861Phase 2Completed
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2014
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin and gemcitabine in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Disease-free survival at 3 years. Started Feb 2014; status: completed.
02
Drugs
cisplatingemcitabine
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT02876861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876861.